Skip to main content

Displaying 1141 - 1160 of 1511

Announced Actions for September 24, 2004

Date
Commission filing of comments with the U.S. Department of Energy: The Commission filed comments with the U.S. Department of Energy (DOE) concerning the designation of National Interest Electric...

Generic Drug Marketers Settle FTC Charges

Date
Generic drug manufacturers Alpharma, Inc. and Perrigo Company will give up $6.25 million in illegal profits to settle Federal Trade Commission charges that their agreement to limit competition for...

Announced Action for August 6, 2004

Date
Commission authorization of staff amicus brief filing: The Commission has authorized the staff to file a joint amicus brief in Spano, et al. v. SAFECO Insurance Co. of America, et al., No 04-35313...

Southeastern New Mexico Physicians IPA, Inc., a corporation, and Barbara Gomez and Lonnie Ray, individually

A Roswell, New Mexico physicians’ association, Southeastern New Mexico Physicians IPA, settled charges that it and two of its employees entered into collective agreements among physician members on fees and refused to deal with health plans that did not accept the collective agreed-upon terms. According to the complaint, these practices increased the price of health care in the Roswell area. The consent order prohibits the IPA and its employees named in the consent from orchestrating agreements between physicians to negotiate with health insurance plans on behalf of any physician and deal or refuse to deal individually with any third party payer.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0310134
Docket Number
C-4113

Announced Action for July 16, 2004

Date
Commission authorization of joint amicus brief filing: The Commission has authorized the filing of a joint amicus brief with the U.S. Department of Justice (DOJ) in Andrx Pharmaceuticals, Inc. v...

Contact Lens Rule

Rule Updated Date
The Contact Lens Rule contains two key requirements. The first requirement is that contact lens prescribers (i.e., optometrists and ophthalmologists) must provide patients with a copy of their contact...

Announced Actions for May 25, 2004

Date
Commission authorization of the staff to file amicus brief: The Commission has authorized the filing of a joint amicus brief with the Department of Justice in McMahon v. Advanced Title Services...

Bristol-Myers Squibb Company, In the Matter of

Bristol-Myers Squibb Company (BMS) settled charges that it engaged in illegal business practices to delay the entry of three low price generic pharmaceuticals that would be in direct competition with three of its branded drugs. The complaint alleged that BMS purposely made wrongful listings in the Orange Book of the U.S. Food & Drug Administration and that it also paid a potential competitor over $70 million to delay the entry of its generic drug. The three drugs involved in the complaint are: Taxol (containing the active ingredient paclitaxel) – used to treat ovarian, breast, and lung cancers; Platinol (containing the active ingredient cisplatin) – used for the treatment of various forms of cancer; and BuSpar (containing the active ingredient buspirone) – used to manage anxiety disorders. To prevent recurrence of Bristol's pattern of alleged improper listings, the consent order eliminates Bristol's ability to obtain a 30-month stay on later-listed patents. By denying Bristol the benefit of the 30-month stay on later-listed patents, the order would reduce Bristol's incentive to engage in improper behavior before the PTO and the FDA to obtain and list a patent for the purpose of obtaining an unwarranted automatic 30-month stay.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
0110046
Docket Number
C-4076

Announced Action for May 11, 2004

Date
Commission approval of final consent order: By a vote of 5-0, the Commission has approved a final consent order and authorized the staff to send letters to the commentors of record in the matter...